Evidence map›Paper›PMID 29568235›Full record

ArticleCancer cell international2018

Transcription factor E2F3a regulates

Fei-Fei Liu, Kai-Ling Wang, Li-Ping Deng, Xiao Liu, Min-Yuan Wu, Tian-You Wang, Lei Cui, Zhi-Gang Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Fei-Fei Liu *Hematology & Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health; Beijing Key Laboratory of Pediatric Hematology Oncology; Key Laboratory of Major Diseases in Children, Ministry of Education; National Key Discipline of Pediatrics, Ministry of Education, Beijing, China.
Kai-Ling Wang *Hematology & Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health; Beijing Key Laboratory of Pediatric Hematology Oncology; Key Laboratory of Major Diseases in Children, Ministry of Education; National Key Discipline of Pediatrics, Ministry of Education, Beijing, China.
Li-Ping DengHematology & Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health; Beijing Key Laboratory of Pediatric Hematology Oncology; Key Laboratory of Major Diseases in Children, Ministry of Education; National Key Discipline of Pediatrics, Ministry of Education, Beijing, China.
Xiao LiuHematology & Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health; Beijing Key Laboratory of Pediatric Hematology Oncology; Key Laboratory of Major Diseases in Children, Ministry of Education; National Key Discipline of Pediatrics, Ministry of Education, Beijing, China.
Min-Yuan WuHematology & Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health; Beijing Key Laboratory of Pediatric Hematology Oncology; Key Laboratory of Major Diseases in Children, Ministry of Education; National Key Discipline of Pediatrics, Ministry of Education, Beijing, China.
Tian-You WangHematology & Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health; Beijing Key Laboratory of Pediatric Hematology Oncology; Key Laboratory of Major Diseases in Children, Ministry of Education; National Key Discipline of Pediatrics, Ministry of Education, Beijing, China.
Lei CuiHematology & Oncology Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health; Beijing Key Laboratory of Pediatric Hematology Oncology; Key Laboratory of Major Diseases in Children, Ministry of Education; National Key Discipline of Pediatrics, Ministry of Education, Beijing, China.
Zhi-Gang LiHematology & Oncology Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health; Beijing Key Laboratory of Pediatric Hematology Oncology; Key Laboratory of Major Diseases in Children, Ministry of Education; National Key Discipline of Pediatrics, Ministry of Education, Beijing, China.
Center for Children · USBeijing Children’s Hospital · CNMinistry of Education of the People's Republic of China · CNBinzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLow expression of

methodsDual-luciferase reporter assay and wild type as well as four mutated types of reporter plasmids were used to demonstrate the activation of E2F3a on

resultsIn this study, we found that up-regulation of E2F3a in leukemic cells led to increased fraction of cells in S and G2/M phase, accelerated proliferation, and enhanced sensitivity to vincristine and daunorubicin. ChIP and luciferase assay indicated that E2F3a could directly bind to two fragments in the wild type of

conclusionsE2F3a could promote transcription and expression of

Indexed as

CASP8AP2Chemotherapeutic sensitivityChildhood acute lymphoblastic leukemiaE2F3aTranscription regulation

Identifiers

PMID29568235
PMCPMC5859744
OpenAlexW2801877774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.